Mastering Current Management of CLL

Join us for this interactive live Webinar featuring expert perspectives on the latest data on managing CLL/SLL, including discussion around patient cases and the opportunity to get your questions answered by the experts.

Thank you for your interest in attending the Clinical Care Options (CCO) live Webinar, “Mastering Current Management of CLL.”

This live Webinar will feature expert faculty, and provide interactivity, evidence-based content, and Q&A session. When participating in a live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

An official independent commercially supported symposium held in conjunction with the Hematology/Oncology Pharmacy Association’s 17th Annual Conference.

Thank you,
CCO Member Services


Welcome, Introduction, Polling Questions

Introduction: Overview of CLL/SLL and Treatment Algorithms – Dr. Sharman

  • Standard-of-care first-line and second-line regimens
  • Key variables in deciding between regimens
  • Mastering the current regimen components
  • On the horizon: measurable residual disease, CAR T-cell therapy, and other hot research areas

Effective Management of CLL by Pharmacists – Dr. Bucholtz

  • Starting systemic therapy in suitable patients
  • Promoting adherence with oral therapy
  • Adverse event profiles and management guides and resources

Summary, Final Thoughts, Audience Q&A


Date / Time
Event Details


Emily Bucholtz, RPh

Willamette Valley Cancer Institution
Eugene, Oregon

Jeff Sharman, MD

Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon

Goal Statement
The goal of this activity is to improve the knowledge and competence of hematology-oncology pharmacists and other healthcare professionals so they can confidently and competently apply the recent improvements in CLL to optimize patient outcomes.

Target Audience
This educational program is intended for hematology-oncology pharmacists and other healthcare providers who care for patients with CLL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss treatment plans for treatment-naive and relasped/refractory CLL/SLL, including consideration of agent differences, biomarkers, comorbidities, and patient preference
  • Describe intraclass differences for agents with the same target in CLL/SLL regarding selectivity, target binding, efficacy, adverse event profiles
  • Formulate strategies to minimize risk for drug–drug interactions with recently approved and emerging systemic therapies in CLL/SLL
  • Evaluate the evolving role of measurable residual disease, allogeneic hematopoietic cell transplant, and CAR T-cell therapy
  • Develop strategies to address unique challenges (eg, identification and management of adverse events, adherence/compliance to treatment) as well ways hematology-oncology pharmacists optimize outcomes for patients with CLL


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. UAN: JA4008176-0000-21-031-L01-P

Type of Activity: Knowledge

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.